

## **Prof.Dr. Sezai VATANSEVER**

### **Kişisel Bilgiler**

**İş Telefonu:** [+90 212 414 2434](tel:+902124142434) Dahili: 34194

**İş Telefonu:** [+90 212 414 2434](tel:+902124142434) Dahili: 34228

**Fax Telefonu:** [+90 212 534 8078](tel:+902125348078)

**E-posta:** [sezai@istanbul.edu.tr](mailto:sezai@istanbul.edu.tr)

**Web:** <http://aves.istanbul.edu.tr/1244/>

**Posta Adresi:** İÜ, Onkoloji Enstitüsü Tıbbı Onkoloji Bilim Dalı Başkanlığı Çapa / Şehremeni / Fatih / İstanbul

### **Uluslararası Araştırmacı ID'leri**

ORCID: 0000-0002-3108-0686

Publons / Web Of Science ResearcherID: AAY-8457-2020

Yoksis Araştırmacı ID: 102278

### **Eğitim Bilgileri**

Tıpta Yandal Uzmanlık, İstanbul Üniversitesi, İstanbul Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü/İç Hastalıkları Anabilim Dalı, Türkiye 2008 - 2011

Tıpta Uzmanlık, İstanbul Üniversitesi, İstanbul Tıp Fakültesi, /Dahili Tıp Bilimleri Bölümü/İç Hastalıkları Anabilim Dalı, Türkiye 1987 - 1993

### **Yabancı Diller**

İngilizce, B2 Orta Üstü

### **Yaptığı Tezler**

Tıpta Uzmanlık, İyi farklılaşmış tiroid kanserinde klinik seyri ve prognozu etkileyen faktörler (143 hastanın incelenmesi) , İstanbul Üniversitesi, İstanbul Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü/İç Hastalıkları Anabilim Dalı, 1996

### **Araştırma Alanları**

Tıp, Sağlık Bilimleri, Dahili Tıp Bilimleri, İç Hastalıkları, Onkoloji

### **Akademik Unvanlar / Görevler**

Prof.Dr., İstanbul Üniversitesi, Onkoloji Enstitüsü, Klinik Onkoloji Ana Bilim Dalı, 2008 - Devam Ediyor

Doç.Dr., İstanbul Üniversitesi, İstanbul Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, 2004 - 2008

Uzman, İstanbul Üniversitesi, İstanbul Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, 1994 - 2004

### **Akademik İdari Deneyim**

İstanbul Üniversitesi, Onkoloji Esntitüsü, 2011 - 2013  
İstanbul Üniversitesi, İstanbul Tıp Fakültesi, 2007 - 2008

## Verdiği Dersler

5. SINIF VAKA DEMONSTRASYONLARI, Lisans, 2015 - 2016  
ONKOLOJİK ACİLLER, Lisans, 2013 - 2014, 2012 - 2013, 2011 - 2012, 2009 - 2010, 2008 - 2009  
PRİMERİ BİLİNMEYEN METASTETİK KANSERLERE YAKLAŞIM, Lisans, 2013 - 2014, 2011 - 2012, 2010 - 2011, 2009 - 2010, 2008 - 2009  
MALİGN EFÜZYONLU HASTAYA YAKLAŞIM, Lisans, 2013 - 2014, 2012 - 2013, 2011 - 2012, 2010 - 2011, 2009 - 2010, 2008 - 2009  
İLK YARDIM, Ön Lisans, 2013 - 2014, 2012 - 2013  
ONKOLOJİK DESTEK TEDAVİSİ, Lisans, 2013 - 2014, 2011 - 2012, 2010 - 2011, 2009 - 2010, 2008 - 2009  
ONKOLOİK DESTEK TEDAVİSİ, Lisans, 2012 - 2013  
ENDOKRİN ACİLLER, Lisans, 2008 - 2009, 2007 - 2008  
SIVI ELEKTROLİT DENGESİ, Lisans, 2008 - 2009, 2007 - 2008  
ASİT BAZ DENGESİ, Lisans, 2008 - 2009, 2007 - 2008  
SENKOP, Ön Lisans, 2008 - 2009, 2007 - 2008  
AKUT BÖBREK YETERSİZLİĞİ, Lisans, 2008 - 2009, 2007 - 2008  
AKUT SOLUNUM YETERSİZLİĞİ, Lisans, 2007 - 2008

## Yönetilen Tezler

VATANSEVER S., Altmış yaş ve üzeri hastalarda demir eksikliği anemisi etyolojisinin araştırılması ve sıklığının saptanması, Tıpta Uzmanlık, M.YÜKSEL(Öğrenci), 2008  
VATANSEVER S., Türk kadınlarda üst kol çevresi ölçümünün fazla kilo ve obezite ile ilişkisi, Tıpta Uzmanlık, M.AKGÜN(Öğrenci), 2005

## SCI, SSCI ve AHCI İndekslerine Giren Dergilerde Yayınlanan Makaleler

- I. Isolated Adrenal Metastases of Castration-Resistant Prostate Cancer  
Topal E., Has Simsek D., Vatansever S., Sanli Y., Kuyumcu S.  
CLINICAL NUCLEAR MEDICINE, cilt.49, sa.1, 2024 (SCI-Expanded)
- II. Immune checkpoint inhibitors Assessment of the performance and the agreement of iRECIST, irRC, and irRECIST  
Kızıldağ Yırgın İ., Dogan İ., Engin G., Vatansever S., Erturk S. M.  
Journal of Cancer Research and Therapeutics, sa.2, ss.1-7, 2023 (SCI-Expanded)
- III. Evaluation of clinicopathological features determining treatment response in patients with ALK mutant NSCLC  
DOĞAN İ., Gurbuz M., Paksoy N., Ferhatoglu F., Vatansever S., Saip P., DEMİRKAZIK A., Aydiner A.  
MEDICINE, cilt.101, sa.34, 2022 (SCI-Expanded)
- IV. Prognostic factors influencing progression-free survival in HER2 positive metastatic breast cancer patients who treated with lapatinib and capecitabine combination.  
Dogan I., Paksoy N., Ak N., Vatansever S., Saip P., Aydiner A.  
JOURNAL OF CLINICAL ONCOLOGY, cilt.40, sa.16, 2022 (SCI-Expanded)
- V. Dramatic response to single-agent atezolizumab in a patient with MSI-H serous ovarian cancer  
Ak N., Vatansever S.  
JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS, cilt.46, sa.6, ss.1787-1791, 2021 (SCI-Expanded)

- VI. **Outcomes of thymoma after multimodal therapy and determinants of survival: A 16-year experience of a tertiary cancer center**  
Ak N., Toker A., Kara M., Ozkan B., Ulker M., Kaba E., Yegen G., Karaman S., Dagoglu N., Saglam E. K., et al.  
TÜRK GOGUS KALP DAMAR CERRAHISI DERGİSİ-TURKISH JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY, cilt.29, sa.4, ss.487-495, 2021 (SCI-Expanded)
- VII. **Predictors of response in EGFR-mutant metastatic non-small cell lung cancer patients treated with tyrosine kinase inhibitors.**  
Aydiner A., Dogan I., Khanmammadov N., Saip P., Vatansever S.  
JOURNAL OF CLINICAL ONCOLOGY, cilt.39, sa.15, 2021 (SCI-Expanded)
- VIII. **Outcomes of ROS1 positive metastatic lung cancer patients treated with crizotinib**  
Dogan I., Khanmammadov N., Paksoy N., Ferhatoglu F., Aydin E., Vatansever S., Saip P., Aydiner A.  
JOURNAL OF THORACIC ONCOLOGY, cilt.16, sa.4, 2021 (SCI-Expanded)
- IX. **Predictors of treatment response in ALK-positive metastatic non-small cell lung cancer**  
Dogan I., Gurbuz M., Paksoy N., Ferhatoglu F., Vatansever S., Saip P., Demirkazik A., Aydiner A.  
JOURNAL OF THORACIC ONCOLOGY, cilt.16, sa.4, 2021 (SCI-Expanded)
- X. **Outcomes and prognostic factors in metastatic renal cell carcinoma patients with brain metastases.**  
Dogan I., Iribas A., Paksoy N., Ekenel M., Vatansever S., Basaran M.  
JOURNAL OF CLINICAL ONCOLOGY, cilt.39, sa.6, 2021 (SCI-Expanded)
- XI. **"Door to Treatment" Outcomes of Cancer Patients during the COVID-19 Pandemic**  
Ak N., Vatansever S.  
CHEMOTHERAPY, cilt.65, sa.5-6, ss.141-146, 2021 (SCI-Expanded)
- XII. **The expression level of fibulin-2 in the circulating RNA (ctRNA) of epithelial tumor cells of peripheral blood and tumor tissue of patients with metastatic lung cancer**  
Avsar M., Tambas M., Yalniz Z., Akdeniz D., Tuncer S., Kilic S., Sukruoglu E., Ciftci R., Dagoglu N., Vatansever S., et al.  
MOLECULAR BIOLOGY REPORTS, sa.4, ss.4001-4008, 2019 (SCI-Expanded)
- XIII. **Vemurafenib-induced toxic epidermal necrolysis: Is it an emerging side-effect of the drug?**  
Kilic S., Ozkaya E., Baykal C., Vatansever S.  
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, cilt.31, 2017 (SCI-Expanded)
- XIV. **Is it solitary plasmacytoma or nonsecretory myeloma? A must-be-solved dilemma?**  
Erturk K., Tastekin D., Gundogdu G., Tas F., Vatansever S.  
BIOMEDICINE & PHARMACOTHERAPY, cilt.77, ss.27-29, 2016 (SCI-Expanded)
- XV. **Clinical significance of serum interleukin-29, interleukin-32, and tumor necrosis factor alpha levels in patients with gastric cancer**  
Erturk K., Tastekin D., Serilmez M., Bilgin E., Bozbey H. U., Vatansever S.  
TUMOR BIOLOGY, cilt.37, sa.1, ss.405-412, 2016 (SCI-Expanded)
- XVI. **The diagnostic, predictive, and prognostic role of serum epithelial cell adhesion molecule (EpCAM) and vascular cell adhesion molecule-1 (VCAM-1) levels in breast cancer**  
Karabulut S., Tas F., Tastekin D., KARABULUT M., Yasasever C., Ciftci R., Guveli M., Fayda M., Vatansever S., Serilmez M., et al.  
TUMOR BIOLOGY, cilt.35, sa.9, ss.8849-8860, 2014 (SCI-Expanded)
- XVII. **Is there any diagnostic value of serum protease-activated receptor-1 (PAR1) levels on determination of epithelial ovarian carcinoma?**  
Karabulut S., Aksit E., Tas F., Ciftci R., Aydiner A., Yildiz I., Keskin S., Eralp Y., Yasasever C. T., Vatansever S., et al.  
Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine, cilt.35, sa.5, ss.4323-9, 2014 (SCI-Expanded)
- XVIII. **Clinical significance of serum circulating insulin-like growth factor-1 (IGF-1) mRNA in hepatocellular carcinoma**  
Karabulut S., Duranyildiz D., Tas F., Gezer U., Akyuz F., Serilmez M., Ozgur E., Yasasever C. T., Vatansever S., Aykan N. F.  
TUMOR BIOLOGY, cilt.35, sa.3, ss.2729-2739, 2014 (SCI-Expanded)
- XIX. **Clinical significance of serum hepatocyte growth factor (HGF) levels in hepatocellular carcinoma**

- Karabulut S., Tas F., Akyuz F., Ormeci A., Serilmez M., Soydinc H. O., Vatansever S., Yasasever V.  
TUMOR BIOLOGY, cilt.35, sa.3, ss.2327-2333, 2014 (SCI-Expanded)
- XX. **High serum transforming growth factor beta 1 (TGFB1) level predicts better survival in breast cancer**  
Ciftci R., Tas F., Yasasever C., Aksit E., Karabulut S., Sen F., Keskin S., Kilic L., Yildiz I., Bozbey H. U., et al.  
Tumor Biology, cilt.35, sa.7, ss.6941-6948, 2014 (SCI-Expanded)
- XXI. **The Role of Surgical Methods in the Treatment of Anorectal Malignant Melanoma (AMM)**  
Keskin S., Tas F., Karabulut S., Yildiz I., Kilic L., Ciftci R., Vatansever S.  
ACTA CHIRURGICA BELGICA, cilt.113, sa.6, ss.429-433, 2013 (SCI-Expanded)
- XXII. **Biweekly triplet chemotherapy with gemcitabine, cisplatin and vinorelbine for advanced chemotherapy naïve non-small cell lung cancer.**  
Keskin S., Tas F., Ekenel M., Kilic L., Sen F., Yildiz I., Karabulut S., Ciftci R., Vatansever S.  
Tumori, cilt.99, sa.4, ss.463-8, 2013 (SCI-Expanded)
- XXIII. **Adrenocortical carcinoma: clinicopathological features, prognostic factors and outcome.**  
Keskin S., Tas F., Vatansever S.  
Urologia internationalis, cilt.90, sa.4, ss.435-8, 2013 (SCI-Expanded)
- XXIV. **A CASE OF PARANEOPLASTIC LIMBIC ENCEPHALITIS DUE TO GASTRIC CARCINOMA PRESENTING WITH PANHYPOPITUITARISM**  
Kayacan S., Vatansever S., Yilmaz A., Kayacan D., Karadag A., Akkaya V., Erk O., Guler K.  
NOBEL MEDICUS, cilt.9, sa.1, ss.121-123, 2013 (SCI-Expanded)
- XXV. **Factors Associated with Late Toxicity in Nasopharyngeal Carcinoma Patients Treated with Radio- Chemotherapy**  
Meral R., Camlica H., Vatansever S.  
TÜRKİYE KLINİKLERİ TIP BİLİMLERİ DERGİSİ, cilt.30, sa.1, ss.37-47, 2010 (SCI-Expanded)
- XXVI. **High Sensitivity C- Reactive Protein In Spontaneous Bacterial Peritonitis with Nonneutrocytic Ascites**  
Guler K., Vatansever S., Kayacan S. M., Salmayenli N., Akkaya V., Erk O., Palanduz A.  
HEPATO-GASTROENTEROLOGY, cilt.56, sa.90, ss.452-455, 2009 (SCI-Expanded)
- XXVII. **Alveolar echinococcosis localized in the liver, lung and brain**  
Kayacan S. M., Vatansever S., Temiz S., Uslu B., Kayacan D., Akkaya V., Erk O., Saka B., Karadag A., Turkmen K., et al.  
CHINESE MEDICAL JOURNAL, sa.1, ss.90-92, 2008 (SCI-Expanded)
- XXVIII. **A case of inflammatory pseudotumor in the spleen**  
CELEBI A., Kayacan S. M., Keskin S., TEMELOGLU E., KOC D., ERCAN V., ESIN D., EKIZOGLU I., Vatansever S., GULLUOGLU M., et al.  
SOUTHERN MEDICAL JOURNAL, cilt.99, sa.7, ss.774-776, 2006 (SCI-Expanded)
- XXIX. **The effect of air pollution and meteorological parameters on chronic obstructive pulmonary disease at an Istanbul hospital**  
Hapcioglu B., Issever H., Kocyigit E., Disci R., Vatansever S., OZDILLI K.  
INDOOR AND BUILT ENVIRONMENT, cilt.15, sa.2, ss.147-153, 2006 (SCI-Expanded)
- XXX. **Effect of apoptosis and response of extracellular matrix proteins after chemotherapy application on human breast cancer cell spheroids**  
OKTEM G., Vatansever S., AYLA S., UYSAL A., AKTAS S., KARABULUT B., BILIR A.  
ONCOLOGY REPORTS, cilt.15, sa.2, ss.335-340, 2006 (SCI-Expanded)
- XXXI. **The effect of air pollution and meteorological parameters in Istanbul on hospital admissions for acute coronary syndrome**  
Issever H., Disci R., HAPCIOGLU B., Vatansever S., Karan M. A., Akkaya V. A., Erk O.  
INDOOR AND BUILT ENVIRONMENT, cilt.14, sa.2, ss.157-164, 2005 (SCI-Expanded)
- XXXII. **Pre-ischemic administration of nitric oxide synthase inhibitors reduced germ cell apoptosis after spermatic vessel ligation in the rat testis**  
Taneli F., VATANSEVER S., Ulman C., Giray G., Genc A., Taneli C.  
UROLOGIA INTERNATIONALIS, cilt.75, sa.1, ss.70-74, 2005 (SCI-Expanded)
- XXXIII. **Sister chromatid exchange and mitotic index in patients with cirrhosis related to hepatitis B and C**

#### **viruses and in chronic carriers**

Ucur A., Palanduz S., Cefle K., Ozturk Ş., Tutkan G., Vatansever S., Erden S., Karan M., Erten N., Guler K., et al.  
HEPATO-GASTROENTEROLOGY, cilt.50, sa.54, ss.2137-2140, 2003 (SCI-Expanded)

#### **XXXIV. Rheological properties of blood in patients with chronic liver disease**

Tamer S., Cefle K., Palanduz S., Vatansever S.

CLINICAL HEMORHEOLOGY AND MICROCIRCULATION, cilt.26, sa.1, ss.9-14, 2002 (SCI-Expanded)

#### **XXXV. Questioning the psycho-socio-cultural factors that contribute to the cases of suicide attempts: an investigation**

Tüzün B., Polat O., Vatansever S., Elmas I.

FORENSIC SCIENCE INTERNATIONAL, cilt.113, ss.297-301, 2000 (SCI-Expanded)

#### **XXXVI. A case of Noonan syndrome with pulmonary and abdominal lymphangiectasia**

Ozturk Ş., Cefle K., Palanduz S., Erten N., Karan M., Tascioglu C., Umman S., Falay O., Vatansever S., Guler K., et al.  
INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, cilt.54, sa.4, ss.274-276, 2000 (SCI-Expanded)

#### **XXXVII. Rheological properties of blood in patients with ischaemic heart disease**

Palanduz S., Tamer S., Vatansever S., Karan M., Cefle K., Ozturk Ş., Guler K., Kudat H., Kayserilioglu A.

MEDICAL SCIENCE RESEARCH, cilt.27, sa.5, ss.327-329, 1999 (SCI-Expanded)

#### **XXXVIII. Total antioxidant status, lipid parameters, lipid peroxidation and glutathione levels in patients with acute myocardial infarction**

Guler K., Palanduz S., Ademoglu E., Salmayenli N., Gokkusu C., Vatansever S.

MEDICAL SCIENCE RESEARCH, cilt.26, sa.2, ss.105-106, 1998 (SCI-Expanded)

### **Düger Dergilerde Yayınlanan Makaleler**

#### **I. Efficacy of Lapatinib Plus Capecitabine After TDM-1 in HER2-Positive Metastatic Breast Cancer Patients**

Dogan I., Yıldız A., Ahmed M. A., Vatansever S.

Indian Journal of Surgical Oncology, 2024 (ESCI)

#### **II. Laterality of Adrenal Gland Metastasis in Lung Cancer: Results of a Comparative Study**

FERHATOĞLU F., ÇAĞATAY T., OKUMUŞ G., AYDINER A., PAKSOY N., VATANSEVER S., AYDIN E., SAİP P.

Eurasian Journal of Medical Investigation, cilt.7, sa.2, ss.101-106, 2023 (Hakemli Dergi)

#### **III. Predictors of the acquisition of T790M mutation in EGFR-mutant metastatic lung cancer patients who were treated with EGFR inhibitors**

DOĞAN İ., KHANMAMMADOV N., PAKSOY N., VATANSEVER S., SAİP P., AYDINER A.

Eurasian Journal of Pulmonology, cilt.25, sa.1, ss.27-32, 2023 (Hakemli Dergi)

#### **IV. Prognostic Factors Influencing Progression-Free Survival in HER2-Positive Metastatic Breast Cancer Patients Who Were Treated with A Combination of Lapatinib and Capecitabine**

DOĞAN İ., Paksoy N., AK N., VATANSEVER S., Saip P., AYDINER A.

European Journal of Breast Health, cilt.19, sa.2, ss.128-133, 2023 (Scopus)

#### **V. The Significance of Preoperative Computed Tomography Features in the Prediction of Overall Survival in Gastric Cancer: A Retrospective Analysis**

Kızıldağ Yırgın İ., Dogan İ., Vatansever S., Erturk S. M.

MEDICAL BULLETIN OF SISLI ETFAŁ HOSPITAL, sa.1, ss.1-5, 2023 (Hakemli Dergi)

#### **VI. Systemic Immune-Inflammation Index as a Prognostic Marker of Late Recurrence in Operable Gastric Cancer: a Dual-Center Study**

Yekeduz E., Dogan İ., Kaya D. M., Ozgur İ., UTKAN G., Vatansever S., DEMİRÇİ S., AKBULUT H., ÜRÜN Y.

JOURNAL OF GASTROINTESTINAL CANCER, cilt.53, sa.4, ss.870-879, 2022 (ESCI)

#### **VII. Outcomes and Prognostic Factors in Patients with EGFR Mutant Metastatic Non-Small Cell Lung Cancer Who Treated with Erlotinib**

DOĞAN İ., Khanmammadov N., Ahmed M. A., Yildiz A., Saip P., Aydiner A., VATANSEVER S.

CLINICAL CANCER INVESTIGATION JOURNAL, sa.4, ss.5-9, 2022 (ESCI)

- VIII. **Crizotinib in Metastatic ALK mutant Non-small Cell Lung Cancer Patients: A Single Centre Experience**  
DOĞAN İ., Khanmammadov N., Ahmed M. A., Yıldız A., Saip P., Aydiner A., VATANSEVER S.  
CLINICAL CANCER INVESTIGATION JOURNAL, sa.3, ss.25-29, 2022 (ESCI)
- IX. **Real-life Outcomes of ROS1 Fusion-positive Metastatic Lung Cancer Patients who were Treated with Crizotinib**  
Dogan I., Khanmammadov N., Paksoy N., Ferhatoglu F., Aydin E., Vatansever S., Aydine A.  
TÜRK ONKOLOJİ DERGİSİ-TURKISH JOURNAL OF ONCOLOGY, cilt.37, ss.413-418, 2022 (ESCI)
- X. **Metastases to the Stomach: Clinicopathologic Features of Metastases Mimicking Gastric Primaries**  
ALTAY A. Y., BÜYÜK M., ÖZGÜR İ., GÖK A. F. K., ÇAVUŞ B., AYDIN E., VATANSEVER S., GÜLLÜOĞLU M.  
TURKISH JOURNAL OF PATHOLOGY, cilt.37, sa.3, ss.203-211, 2021 (ESCI)
- XI. **Evaluation of Prognostic and Predictive Values of Hemogram Parameters in Patients with Advanced Stage Ovarian Carcinoma**  
Naziye A. K., Paksoy N., Ferhatoglu F., Aydin E., Dogan I., Bektas E., Karaca M., Oguz Soydinc H., Minareci Y., Sozen H., et al.  
TÜRK ONKOLOJİ DERGİSİ-TURKISH JOURNAL OF ONCOLOGY, cilt.36, ss.438-445, 2021 (ESCI)
- XII. **Nectin-2 and Nectin-4 Adhesion Molecules in Patients with Breast Cancer**  
Ak N., Serilmaz M., Ucuncu M. Z., Bademler S., Vatansever S.  
TÜRK ONKOLOJİ DERGİSİ-TURKISH JOURNAL OF ONCOLOGY, cilt.36, sa.2, ss.165-170, 2021 (ESCI)
- XIII. **Rare pancreas tumor mimicking adenocarcinoma: Extramedullary plasmacytoma**  
AKYÜZ F., Sahin D., Akyuz U., VATANSEVER S.  
WORLD JOURNAL OF GASTROINTESTINAL ENDOSCOPY, cilt.6, sa.3, ss.99-100, 2014 (ESCI)
- XIV. **A CASE OF LEPTOSPIROSIS PRESENTING WITH NEPHROTIC SYNDROME, ACUTE RENAL FAILURE AND THROMBOCYTOPENIA**  
Kayacan S. M., VATANSEVER S., Karada A., ERK O., Kilic L., Bal H., Akkaya V., GÜLER K.  
JOURNAL OF ISTANBUL FACULTY OF MEDICINE-ISTANBUL TIP FAKULTESİ DERGİSİ, cilt.72, sa.1, ss.25-28, 2009 (ESCI)
- XV. **A CASE OF COPPER SULFATE INTOXICATION THAT IS PRESENTED WITH PROLONGED HEMOLYSIS AND ACUTE RENAL FAILURE**  
Kayacan S. M., VATANSEVER S., Akkaya V., ERK O., Tukek T., KILIÇASLAN İ., YILDIZ A., GÜLER K.  
JOURNAL OF ISTANBUL FACULTY OF MEDICINE-ISTANBUL TIP FAKULTESİ DERGİSİ, cilt.70, sa.2, ss.47-50, 2007 (ESCI)
- XVI. **CANDIDA KEFYR PNEUMONIA**  
Kocabay G., Aydin S., Tiryak B., VATANSEVER S., ERK O., Akkaya V., GÜLER K.  
JOURNAL OF ISTANBUL FACULTY OF MEDICINE-ISTANBUL TIP FAKULTESİ DERGİSİ, cilt.68, sa.1, ss.26-28, 2005 (ESCI)
- XVII. **A CASE OF METHEMOGLOBINEMIA INDUCED BY THE ADMINISTRATION OF PRILOCAINE PRIOR TO AN EPILATION PROCEDURE**  
Turkmen E., Kocabay G., YAVUZ A. F., ÖZTÜRK S., VATANSEVER S., Akkaya V., ERK O., GÜLER K.  
JOURNAL OF ISTANBUL FACULTY OF MEDICINE-ISTANBUL TIP FAKULTESİ DERGİSİ, cilt.68, sa.1, ss.19-21, 2005 (ESCI)
- XVIII. **UNILATERAL RENALARTERY THROMBOEMBOLISM IN A PATIENT WITH ATRIAL FIBRILLATION**  
ELİTOK A., Yılmaz C., Karakaya D., Barman A., VATANSEVER S., Akkaya V., ERK O., GÜLER K.  
JOURNAL OF ISTANBUL FACULTY OF MEDICINE-ISTANBUL TIP FAKULTESİ DERGİSİ, cilt.68, sa.2, ss.53-55, 2005 (ESCI)
- XIX. **Evde Hazırlanmış Konserve Bezelye Yenilmesi Sonucu Tip A Nörotoksinine Bağlı Botulism Vakası**  
TÜRKMEKN E., KOCABAY G., SOYLUK SELÇUKBİRİCİK Ö., VATANSEVER S., GÜLER K., AKKAYA V. A., DİLMENER M.  
İstanbul Tıp Fakültesi Mecmuası, 2003 (Hakemli Dergi)

- I. **The role of surgical methods in the treatment of anorectal malignant melanoma (AMM).**  
VATANSEVER S., TAŞ F., Yıldız I., Kılıç L., Çiftci R., Karabulut S., KESKİN S.  
Acta Chirurgica Belgica, İstanbul, 2013
- II. **KOMA**  
VATANSEVER S., TAŞCIOĞLU C., KARAN M. A., BEŞİŞİK S. F., KRESPİ Y.  
ACİL DAHİLİYE, CALANGU S., GULER K., Editör, Nobel Tıp Kitabevleri Ltd. Şti., İstanbul, ss.677-694, 2009
- III. **ZEHİRLENMELER**  
VATANSEVER S., GÜLER K.  
ACİL DAHİLİYE, CALANGU S., GULER K., Editör, Nobel Tıp Kitabevleri Ltd. Şti., İstanbul, ss.657-675, 2009
- IV. **Preoperatif dönemde tıbbi konsültasyonun önemi ve bekłentiler.**  
TUĞRUL K. M., VATANSEVER S.  
Perioperatif iç hastalıkları konsültasyonu, Mehmet Akif Karan, Editör, Nobel Tıp Kitabevi, İstanbul, ss.9-18, 2003

### Hakemli Kongre / Sempozyum Bildiri Kitaplarında Yer Alan Yayınlar

- I. **Non-operative management in locally advanced distal rectal cancer patients with clinical complete response after consolidation chemoradiotherapy: A single center experience**  
Kulle C. B., Özgür İ., Bayraktar A., Güden İ., Karaman Ş., Vatansever S., Acunaş B., Bulut M. T., Keskin M.  
ESCP 17th Scientific & Annual Meeting, Dublin, İrlanda, 21 - 23 Eylül 2022, cilt.24, sa.1, ss.1-315
- II. **Outcomes and prognostic factors in patients with HER2-positive metastatic breast cancer with brain metastasis**  
Dogan I., Kızıldağ Yırgın İ., Özkurt S., İbiş K., Vatansever S., Saip P. M., Aydiner A.  
2022 ASCO Annual Meeting, Illinois, Amerika Birleşik Devletleri, 3 - 07 Haziran 2022, ss.14002
- III. **Evaluation of the relationship between clinicopathological features at diagnosis and acquisition of T790M resistance mutation in patients with EGFR-mutant metastatic lung cancer**  
Dogan I., Khanmamadov N., Paksoy N., Vatansever S., Saip P., Aydiner A.  
Molecular Analysis for Precision Oncology Virtual Congress, ELECTR NETWORK, 7 - 09 Ekim 2021, cilt.32
- IV. **Predictors of osimertinib response at second-line treatment in EGFR mutant non-small cell lung cancer patients with acquired T790M resistance mutation**  
Dogan I., Gurbuz M., Paksoy N., Khanmamadov N., Vatansever S., Saip P., Demirkazik A., Aydiner A.  
Molecular Analysis for Precision Oncology Virtual Congress, ELECTR NETWORK, 7 - 09 Ekim 2021, cilt.32
- V. **The Significance Of Preoperative Computed Tomography Features In The Prediction Of Overall Survival In Gastric Cancer: A Retrospective Analysis.**  
Kızıldağ Yırgın İ., Ertürk S. M., Dogan I., Vatansever S.  
ECR2021, Vienna, Avusturya, 3 - 07 Mart 2021, ss.10-11
- VI. **iRECIST, irRC and irRECIST: A Pairwise Agreement and Performance Evaluation Study**  
Kızıldağ Yırgın İ., Doğan İ., Vatansever S., Ertürk Ş. M.  
RSNA2020, Illinois, Amerika Birleşik Devletleri, 24 - 29 Kasım 2020, ss.988
- VII. **BAĞIŞIKLIK KONTROL NOKTASI İNHİBİTÖRLERİ: İRECIST, İRRC VE İRRECIST'İN PERFORMANSLARININ VE UYUMLARININ DEĞERLENDİRİLMESİ IMMUNE CHECKPOINT İNHİBİTÖRS: ASSESSMENT OF THE PERFORMANCE AND THE AGREEMENT OF İRECIST, İRRC AND İRRECIST**  
Kızıldağ Yırgın İ., Doğan İ., Vatansever S., Ertürk Ş. M.  
41.Uluslararası Radyoloji Kongresi, Antalya, Türkiye, 24 Ekim - 01 Kasım 2020, ss.205-206
- VIII. **Trastuzumab-based treatment of HER2-positive metastatic gastric cancer**  
Dogan I., Karabulut S., Tastekin D., Paksoy N., Sakar B., Vatansever S.  
ESMO 22nd World Congress on Gastrointestinal Cancer, ELECTR NETWORK, 1 - 04 Temmuz 2020, cilt.31
- IX. **Mide Kanserinde Serum Interleukin-29, Interleukin-32 ve Tumor Necrosis Factor Alpha'nın Klinik Önemi**  
ERTÜRK K., TAŞTEKİN D., SERİLMEZ M., BİLGİN DOĞRU E., H. U., VATANSEVER S.  
3. Ulusal İmmüno-Onkoloji ve Hedefe Yönelik Kanser Tedavileri Kongresi, Antalya, Türkiye, 11 - 15 Mayıs 2016, ss.1

- X. **Clinical significance of serum claudin-7 levels in patients with colorectal cancer.**  
Aydogan F., Karabulut M., Alis H., Karabulut S., Celebi K., Bozbey H. U., Erturk K., Vatansever S., Aykan N. F.  
Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) / Clinical Science Symposium on Predicting and Improving Adverse Outcomes in Older Adults with Cancer, Illinois, Amerika Birleşik Devletleri, 29 Mayıs - 02 Haziran 2015, cilt.33
- XI. **Do serum nectin-2 levels have a prognostic effect in patients with colorectal cancer?**  
Basaran M., KARABULUT S., KARABULUT M., GUNALDI M., ALIS H., Erturk K., Vatansever S., Sakar B., Aykan N. F.  
Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) / Clinical Science Symposium on Predicting and Improving Adverse Outcomes in Older Adults with Cancer, Illinois, Amerika Birleşik Devletleri, 29 Mayıs - 02 Haziran 2015, cilt.33
- XII. **Factors affecting progression free survival in non-HIV related classical Kaposi sarcoma.**  
Sen F., Tambas M., Ciftci R., Toz B., Kilic L., Bozbey H. U., Karanlik H., Kurul S., Vatansever S., Saip P., et al.  
Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) / Clinical Science Symposium on Predicting and Improving Adverse Outcomes in Older Adults with Cancer, Illinois, Amerika Birleşik Devletleri, 29 Mayıs - 02 Haziran 2015, cilt.33
- XIII. **Prognostic roles of serum NEDD9 levels in patients with gastric cancer.**  
Karabulut S., Karabulut M., Alis H., Bozbey H. U., Sakar B., Vatansever S., Aykan N. F.  
Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) / Clinical Science Symposium on Predicting and Improving Adverse Outcomes in Older Adults with Cancer, Illinois, Amerika Birleşik Devletleri, 29 Mayıs - 02 Haziran 2015, cilt.33
- XIV. **Clinical significance of serum vascular cell adhesion molecule-1(VCAM-1) in colorectal cancer**  
Ciftci R., Aykan N. F., Aksit E., YASASEVER C. T., Vatansever S., Yasasever V.  
Gastrointestinal Cancers Symposium, San-Francisco, Kostarika, 15 - 17 Ocak 2015, cilt.33
- XV. **Clinical significance of serum macrophage migration inhibitory factor (MIF) level in breast cancer.**  
CIFTCI R., Tas F., AKSIT E., Vatansever S., KARABULUT S., Sen F., YILDIZ I., Keskin S., BOZBEY H. U., Kilic L., et al.  
50th Annual Meeting of the American-Society-of-Clinical-Oncology, Illinois, Amerika Birleşik Devletleri, 30 Mayıs - 03 Haziran 2014, cilt.32
- XVI. **Clinical significance of serum transforming growth factor beta 1 (TGFB1) level in breast cancer.**  
CIFTCI R., Tas F., Kilic L., Vatansever S., KARABULUT S.  
50th Annual Meeting of the American-Society-of-Clinical-Oncology, Illinois, Amerika Birleşik Devletleri, 30 Mayıs - 03 Haziran 2014, cilt.32
- XVII. **AKÇİĞER KANSERLİ HASTALARDA FİBULİN-2 GENİNİN ARAŞTIRILMASI**  
avşar m., AKDENİZ ÖDEMİŞ D., TUNÇER Ş. B., çiftçi r., DAĞOĞLU R. N., ahmedova a., TAMBAŞ M., POYRAZ K., VATANSEVER S., YAZICI H.  
6. ulusal akciğer kanser kongresi, Antalya, Türkiye, 8 - 11 Mayıs 2014
- XVIII. **Meme Kanserli Hastalarda Serum Par-1 (Protease Activated Receptor-1) Düzeylerinin Klinik Açıdan Önemi**  
Ciftci R., Karabulut S., Aksit E., TAŞ F., TİLGEN YASASEVER C., VATANSEVER S., DURANYILDIZ H. D., Kilic L.  
5. Türk Tıbbi Onkoloji Kongresi, Antalya, Türkiye, 19 - 23 Mart 2014, ss.500
- XIX. **Epitelyal Over Kanserli Hastalarda Yüksek Serum Epidermal Büyüme Faktör Reseptörü (EGFR) Düzeyleri Kötü Progresyonuz Sağkalımla İlişkilidir**  
Karabulut S., Ciftci R., Tastekin D., TİLGEN YASASEVER C., VATANSEVER S., Duranyildiz D., TAŞ F., Aydiner A., SAİP P. M.  
5. Türk Tıbbi Onkoloji Kongresi, Antalya, Türkiye, 19 - 23 Mart 2014, ss.428
- XX. **Serum Transforme Edici Büyüme Faktörü-Beta1 (TGF-B1) Seviyelerinin Epitelyal Over Kanserli Hastalarda Klinik Önemi**  
Karabulut S., Ciftci R., Tastekin D., VATANSEVER S., TAŞ F., TİLGEN YASASEVER C., DURANYILDIZ H. D., Aydiner A., SAİP P. M.  
5. Türk Tıbbi Onkoloji Kongresi, Antalya, Türkiye, 19 - 23 Mart 2014, ss.421
- XXI. **Meme Kanserli Hstalarda Serum MIF (Macrophage Migration Inhibitory Factor) Düzeylerinin Klinik Açıdan Önemi**

- Ciftci R., Karabulut S., TİLGEN YASASEVER C., Aksit E., Yildiz I., BİLGİN DOĞRU E., Tas F., Vatansever S., Keskin S., VATANSEVER S., et al.  
5. Türk Tıbbi Onkoloji Kongresi, Antalya, Türkiye, 19 - 23 Mart 2014, ss.501
- XXII. **Serum Hücresel Adhezyon Molekülleri (VCAM-1, EPCAM) Seviyelerinin Meme Kanserli Hastalarda Tanısal, Prediktif ve Prognostik Rolü**  
Karabulut S., Ciftci R., Tastekin D., VATANSEVER S., Aydiner A., TİLGEN YASASEVER C., Duranyıldız D., SAİP P. M.  
5. Türk Tıbbi Onkoloji Kongresi, Antalya, Türkiye, 19 - 23 Mart 2014, ss.493
- XXIII. **Clinical significance of serum protein and mRNA level of insulin-like growth factor-1 (IGF-1) in patients with hepatocellular carcinoma**  
Karabulut S., Aykan N. F., Yildiz I., Kilic L., Sen F., Vatansever S.  
Gastrointestinal Cancers Symposium, San-Francisco, Kostarika, 16 - 18 Ocak 2014, cilt.32
- XXIV. **Clinical significance of coagulation assays in metastatic pancreas adenocarcinoma**  
VATANSEVER S., Tas F., Yildiz I., Kilic L., Ciftci R., Karabulut S., Keskin S.  
7th ECCO / 38th ESMO / 32nd ESTRO European Cancer Congress on Reinforcing Multidisciplinarity, Amsterdam, Hollanda, 27 Eylül - 01 Ekim 2013, cilt.49, ss.600-601
- XXV. **Prognostic factors in metastatic pancreatic cancer: Older patients have poorer prognosis**  
Ciftci R., Karabulut S., Aydogan F., Kilic L., Keskin S., Yildiz I., Vatansever S., Tas F.  
European Cancer Congress 2013 - 17th ECCO / 38th ESMO / 32nd ESTRO, Amsterdam, Hollanda, 27 Eylül - 01 Ekim 2013, cilt.49
- XXVI. **İstanbul Üniversitesi Biyomedikal ve Klinik Mühendisliği Birimi'nde ISO 9001:2008 Kalite Yönetim Sistemi Uygulaması**  
SEZDİ M., ODABAŞIOĞLU N., AKAN A., SELVİ Y., VATANSEVER S.  
Tıp Teknolojileri Ulusal Kongresi, Antalya, Türkiye, 14 - 16 Ekim 2010, ss.69-71
- XXVII. **Tıbbi Cihaz Kazalarında Olay Bildirimi**  
AKAN A., SELVİ Y., VATANSEVER S., Sezdi M.  
8. Uusal Sağlık Kuruluşları Yönetimi Kongresi, SYD-2010, Muğla, Türkiye, 13 - 16 Mayıs 2010, ss.429-432
- XXVIII. **Tıbbi Cihaz Satın Alma Süreçlerinin Yönetimi**  
Sezdi M., AKAN A., SELVİ Y., VATANSEVER S.  
8. Uusal Sağlık Kuruluşları Yönetimi Kongresi, SYD-2010, Muğla, Türkiye, 13 - 16 Mayıs 2010, ss.38-44
- XXIX. **Medikal Kalibrasyonun Hasta Güvenliği Açısından Önemi, Kontrolü ve Akreditasyon**  
SEZDİ M., ÖZSARI S. H., SELVİ Y., VATANSEVER S., AKAN A.  
", II. Uluslararası Sağlıkta Performans ve Kalite Kongresi, Antalya, Türkiye, 28 Nisan - 01 Mayıs 2010, ss.73-77
- XXX. **A case of acute renal failure due to copper sulfate intoxication**  
Kayacan S. M., Vatansever S., Akkaya V., Erk O., Guler K.  
43rd ERA-EDTA Congress, Glasgow, Birleşik Krallık, 15 - 18 Temmuz 2006, cilt.21, ss.110

## **Metrikler**

Yayın: 91  
Atif (WoS): 194  
Atif (Scopus): 200  
H-İndeks (WoS): 9  
H-İndeks (Scopus): 9